We apply established workflows to evaluate projects and entire portfolios to support decision-making and prioritization.
We support companies to develop clinical development strategies that drive competitive differentiation through an adequate choice of trial design elements, such as powering, endpoints and comparators.
We have developed a structured approach to help companies adapt and design Corporate and R&D Strategies that link vision and goals.
Catenion’s proprietary ASAP is a structured and validated process to screen and select the most fitting companies or assets for potential acquisition or licensing.
We conduct an established and comprehensive process for the identification and prioritization of the most fitting and attractive biological targets for an asset or technology platform of interest.
We provide investors with thorough Commercial Due Diligences of lead assets of potential target companies.
Catenion’s proprietary Risk Assessment tool identifies technical and scientific risks of an R&D program based on over 500 criteria with pre-defined scores and weights.
We map landscapes for a given technology or type of therapy
Our Therapeutic Expansion process allows for a systematic search, identification and prioritization of indications that best fit our client’s asset, in line with strategy and needs.
Our Disease Mapping evaluates the current state, future scenarios
David Berry
Valo Health / Flagship Pioneering
CEO / General Partner
Dr. Stefan Oschmann
Merck KGaA
CEO
Dr. Wolfgang Plischke
Bayer Pharma
CEO
Mike Sherman
Endocyte
CEO
Jon P. Stonehouse
Biocryst Pharmaceuticals Inc.
President and CEO
Catenion was founded in 2003 by its four senior partners. For over 19 years, we have been helping our clients develop actionable competitive strategies.
Catenion has worked with over 200 companies, from small biotechs to big pharma across the world.
Our consultants have successfully delivered more than 1500 projects over the years.
All together, our consultants speak 15+ languages, so wherever we are in the world, we connect with people and respect local cultures.
Catenion was founded in 2003 by its four senior partners. For over 19 years, we have been helping our clients develop actionable competitive strategies.
Catenion has worked with over 200 companies, from small biotechs to big pharma across the world.